The frequently reported adverse effects of PCSK9 inhibitors in clinical practice encompass myalgia (27.2%), back pain (12%), nasopharyngitis (9.3%), headache (9.2%), upper respiratory tract infections (9%), flu-like symptoms (7.5%), and joint pain (7%)., with a notable incidence of myalgia in post-marketing surveillance studies [174, 178]. The gene discussed is PCSK9; the disease is Myalgia.